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Clozapine is strongly associated with the 
risk of pneumonia and inflammation
Jose de Leon  ,1 Can- Jun Ruan,2 Hélène Verdoux,3 
Chuanyue Wang2
AbstrAct
Clinicians need to remember that (1) systemic 
inflammations can increase clozapine level; (2) 
clozapine, by itself, can cause inflammation, 
particularly during titration that is too rapid for 
that patient; (3) clozapine may increase the risk 
of infection; and (4) more specifically, clozapine 
may be particularly strongly associated with 
the risk of pneumonia. Pneumonia appears to 
be associated with high mortality in clozapine 
patients around the world. Clinicians who are 
alert to the risk of pneumonia in clozapine 
patients may significantly decrease mortality in 
clozapine patients. There is no data on COVID-19 
infections in clozapine patients, but based on 
what we know about clozapine pharmacology, 
we can hypothesise that clozapine, possibly 
by impairing immunological mechanisms, may 
increase the risk of pneumonia in infected 
patients. More importantly, once fever and/or 
pneumonia develops, the clozapine dose should 
be cut in half to decrease the risk of clozapine 
intoxication. If there is any doubt that in spite of 
halving the dose there are still signs of clozapine 
intoxication, completely stopping clozapine may 
be indicated. Once the signs of inflammation and 
fever have disappeared, the clozapine dose can 
be increased to the prior dosage level.
IntroductIon
This forum article reviews the multi-
faceted relationship of clozapine and 
inflammation and its impact on the 
clinical care of patients. After briefly 
reviewing clozapine metabolism, 
four major topics are discussed: (1) 
inflammation can increase clozapine 
levels; (2) clozapine can cause inflam-
mation, particularly during titration; 
(3) clozapine may increase the risk of 
infection; and (4) more specifically, 
clozapine may be particularly strongly 
associated with the risk of pneumonia.
This data provides a consistent 
pattern, but the studies are limited by 
their observational nature. Obviously 
for ethical reasons, it is not possible 
to randomise clozapine patients to 
infections versus placebo.
There is no data on COVID-19 
in clozapine patients, but based on 
what we know about clozapine phar-
macology, we can hypothesise that 
clozapine, possibly by impairing 
immunological mechanisms, may 
increase the risk of pneumonia in 
infected patients. More importantly, 
once fever and/or pneumonia 
develops, the clozapine dose should 
be cut in half to decrease the risk 
of clozapine intoxication. If there is 
any doubt that in spite of halving the 
dose there are still signs of clozapine 
intoxication, completely stopping 
clozapine may be indicated. Once the 
signs of inflammation and fever have 
disappeared, the clozapine dose can 
be increased to the prior dosage level.
clozApIne metAbolIsm
In 1989 before pharmacokinetic 
studies were required, the United 
States (US) Food and Drug Admin-
istration (FDA) approved clozapine 
with very limited information on 
clozapine metabolism. In 1994, 
Bertilsson et al1 described CYP1A2 as 
its major metabolic pathway. CYP1A2 
pharmacology is highly relevant in 
clozapine dosing. Norclozapine is 
the main metabolite of clozapine 
and appears to be mainly eliminated 
by the kidney, since its conjugated 
metabolites are present in the urine 
and the serum free norclozapine is 
excreted by an unknown renal trans-
porter that can be inhibited by gemfi-
brozil. With geriatric age, clozapine 
clearance from the body decreases; 
this is probably explained by the 
decrease in renal function and subse-
quent decrease in renal clearance of 
norclozapine and other metabolites 
eliminated in the urine.
Tobacco smoke has polycyclic 
aromatic hydrocarbons which bind 
to the aryl hydrocarbon receptor and 
induce CYP1A2 expression, increasing 
the levels of CYP1A2, which is mainly 
expressed in the liver. Therefore, 
smokers tend to have serum concen-
tration values that are approximately 
0.80 that of non- smokers when using 
the same clozapine dose.2 Conversely, 
oestrogens have inhibitory effects on 
CYP1A2 activity. Male patients, then, 
tend to have serum concentration 
values that are approximately 0.86 
that of females when using the same 
clozapine dose.2 Co- medication with 
inducers such as carbamazepine, 
phenytoin or rifampicin increase 
clozapine metabolism and decrease 
clozapine levels. The most important 
inhibitors of clozapine metabolism 
are ciprofloxacin, oral contracep-
tives, fluvoxamine and caffeine in 
high doses. Valproic acid can be 
an inducer and/or an inhibitor of 
clozapine metabolism; this varies 
from patient to patient and over time. 
During clozapine titration, clinicians 
should be more concerned about the 
potential of valproic acid to act as an 
inhibitor.
Clozapine is prone to cause side 
effects, called adverse drug reactions 
(ADRs) by pharmacologists. Some of 
these clozapine ADRs, such as seda-
tion, hypersalivation, constipation 
and seizures, are dose- related. It is 
probably more accurate to describe 
them as serum concentration- related. 
An expert guideline recommends 
for efficacy in schizophrenia trough 
steady- state clozapine concentrations 
of 350–600 ng/mL.3 This indicates a 
narrow therapeutic index. The serum 
concentration of norclozapine does 
not contribute to antipsychotic effi-
cacy since norclozapine has no anti-
psychotic activity. On the other hand, 
it is possible that serum norclozapine 
concentration may contribute to most 
or all clozapine ADRs.
If clinicians have access to clozapine 
levels, they should use them to main-
tain each clozapine patient on the 
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lowest dose possible that provides 
stable trough steady- state clozapine 
levels within the therapeutic range. 
Assuming that the patient practices 
good medical adherence and is reli-
able, we recommend establishing a 
clozapine dose that provides stable 
serum concentrations between 350 
and 400 ng/mL, to allow some room 
for normal fluctuations in the clinical 
environment. To increase compli-
ance and reduce daily ADRs, a single 
administration at night can be used.
Clozapine dosing is not only influ-
enced by geriatric age, smoking, 
gender and co- medication but 
ethnicity (Asian vs non- Asian). 
In 1997, Asian researchers first 
described Chinese patients as having 
serum concentrations similar to 
those of Caucasians with only half 
the clozapine dose used in the US.4 5 
A meta- analytic review2 showed that 
Chinese and other East Asians have 
lower clozapine clearance than 
Caucasians. The lower clozapine 
clearance, probably explained by 
lower CYP1A2 activity, appears to be 
present not only in Chinese patients 
but is also common to other Asians.6 
The FDA describes Asians as those 
people whose ancestral origins range 
geographically from Pakistan to 
Japan.6 In Asians, to reach 350 ng/mL, 
a non- smoking female with average 
metabolism needs around 150 mg/
day and a male smoker 300 mg/day, 
requiring typical doses in Asians from 
150 to 300 mg/day.6 On the other 
hand, a non- smoking US Caucasian 
female with average clozapine metab-
olism needs around 300 mg/day while 
a US Caucasian male smoker needs 
600 mg/day, requiring typical doses 
in the US from 300 to 600 mg/day.6
To define clozapine poor metabo-
lisers (PMs), it is necessary to stratify 
Asians versus non- Asians. Within 
the ethnic group, taking powerful 
clozapine inhibitors and/or being 
severely obese can be explained as 
being a phenotypic PM. In five Asian 
samples, around 7% of the patients 
(2%–13%) were phenotypic PMs, 
with no known cause, but four of the 
five studies were limited by not ruling 
out current inflammation, which can 
make a patient look temporarily like 
a clozapine PM.7 Thus, it is possible 
that around 7% (2%–13%) of Asians 
may have unknown genetic mutations 
possibly at the CYP1A2 gene associ-
ated with being a clozapine PM.7
Until there is a better definition 
of clozapine PMs, we recommend 
considering Asian clozapine PMs 
as those who reach concentrations 
of 350 ng/mL with clozapine doses 
<150 mg/day. A more precise defini-
tion, including smoking and gender 
stratification, is provided in a review 
article.6 Asian female non- smokers 
who are PMs need a clozapine dose 
around 50 mg/day to reach 350 ng/
mL, while Asian male smokers who 
are PMs need a clozapine dose 
around 125 mg/day.6 Until a better 
definition of clozapine PMs in non- 
Asians is established, we recommend 
considering non- Asian clozapine PMs 
as those who reach 350 ng/mL with 
clozapine doses <300 mg/day.2
InflAmmAtIon cAn IncreAse 
clozApIne levels
The US package insert for theophyl-
line, a drug metabolised by CYP1A2, 
indicates that upper respiratory 
infections with fever increase serum 
theophylline concentrations. The 
release of cytokines during the infec-
tion decreases the activity and/or 
expression of CYP1A2. More relevant 
for clinicians, experts on theophyl-
line8 recommended that the theoph-
ylline dose should be approximately 
halved to avoid intoxication during 
these infections. Therefore, the first 
author reduced the clozapine dose 
by half8 when he first diagnosed a 
clozapine intoxication during an 
upper respiratory infection with fever 
in one of his patients. The later arrival 
of the clozapine serum concentration 
level verified his diagnosis of clozapine 
intoxication.8 In 2004, based on this 
case9 and the available literature, he 
proposed that during severe inflam-
mations/infections, including pneu-
monia, the clozapine dose should be 
halved until clozapine levels are avail-
able to better personalise clozapine 
dosing.9 Through 2016, there are 40 
published cases of clozapine elevation 
during infections.10 There are also 
published clozapine intoxications 
during severe inflammation without 
infection.11
More recently, in a Beijing hospital, 
three cases of clozapine intoxication 
we identified included ones with pneu-
monia,12 influenza11 and dermatitis in 
the absence of infection.11 In these 
three Chinese patients severe infec-
tions were associated with roughly 
double the serum concentrations,11 12 
while the effects in relation to derma-
titis depended more on its severity. 
A doubling of the concentration was 
only observed when there was an eleva-
tion of the serum C- reactive protein 
(CRP) and widespread effect on the 
skin all over the body.11 In a recent 
retrospective review of 131 clozapine 
inpatients at Beijing Anding Hospital, 
we found 18 episodes of infections/
inflammations in 16 patients. At the 
total sample level, these episodes: (1) 
extended for 2% (482/24 789) of 
clozapine days and (2) contaminated 
3% (46/1384) of trough steady- state 
serum concentrations of clozapine. 
At the individual level, we found: 
(1) no clinically relevant effects on 
the serum clozapine concentrations 
in the 11% of infection episodes 
which presented with no leukocytosis 
or CRP elevations; (2) halving the 
clozapine dose would be advisable in 
61% of the infection episodes; and 
(3) reducing the clozapine dose to 
one- third would be advisable in 28% 
of infection episodes.13
Therefore, based on the US8 14 
and Chinese experiences11–13 as well 
as on the literature,10 we proposed 
that clinicians need to be very alert 
regarding clozapine patients’ risk of 
clozapine intoxications during any 
kind of systemic inflammation asso-
ciated with fever and/or CRP eleva-
tions. Until better data is available, 
based on our experience in the US 
and China, we have developed three 
sets of recommendations regarding 
infection, based on timeframe: (1) 
prevention; (2) during the infection; 
and (3) after the infection.13
For prevention, we recommend 
that psychiatrists using clozapine 
should educate their outpatients and 
families to be attentive to signs or 
symptoms of infection/inflammation 
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or fever and to contact them imme-
diately to prevent clozapine intoxica-
tions. Moreover, a careful clinician, 
after reaching a stable maintenance 
clozapine dose, should go ahead 
and measure two or three trough 
and steady- state serum clozapine 
concentrations. By calculating the 
mean concentration and correcting 
by the clozapine dose,2 the clinician 
can establish a baseline for clozapine 
metabolism in that patient and the 
lowest clozapine dose providing a 
therapeutic serum concentration. In 
the unfortunate event that the patient 
develops a systemic infection or 
inflammation, this baseline clozapine 
metabolism can be compared with 
the decreased metabolism during the 
inflammation.
Once an infection has developed, 
the psychiatrist should order a CRP 
level. When fever and/or CRP eleva-
tions develop, the psychiatrist should 
consider immediately halving the 
clozapine dose and monitor for signs 
of clozapine intoxication. If the clini-
cian has access to clozapine Thera-
peutic drug monotoring (TDM) when 
the lab returns the clozapine TDM, it 
will be possible to better adjust the 
dosage. If signs of clozapine intoxi-
cation are already present it may be 
safer to stop clozapine for 2–3 days or 
until the serum clozapine concentra-
tion report arrives.
After the infection/inflamma-
tion has resolved and the CRP has 
normalised, we recommend going 
back to the prior clozapine dose 
without uptitration, since half of the 
dose during infection will provide 
roughly the same concentration as 
the dose without infection. If the 
clinician did not measure clozapine 
concentrations before the infection, 
it may be wise to measure them after 
the infection to establish the lowest 
clozapine dose providing therapeutic 
serum concentrations and efficacy for 
maintenance treatment.
Other antipsychotics may be asso-
ciated with elevations in serum 
concentrations during infections or 
inflammations, particularly those 
metabolised by CYP1A2 and CYP3A4. 
Olanzapine is mainly metabolised 
by CYP1A2 and was associated with 
increases in serum concentrations 
during an upper respiratory infection 
in a case report8 but it has a wider 
therapeutic index than clozapine. 
Some case reports and observa-
tional studies previously reviewed 
in another article11 suggest that 
infections can increase the serum 
concentrations of antipsychotics 
metabolised by CYP3A4. Three 
second- generation antipsychotics are 
mainly metabolised by CYP3A4: carip-
razine, quetiapine and lurasidone. 
Four second- generation antipsy-
chotics are metabolised by CYP2D6 
and CYP3A4: aripiprazole, brexpip-
razole, iloperidone and risperidone. 
Until better studies are available, we 
recommend that clinicians remain 
aware of this potential for increases 
in serum concentration levels during 
infections/inflammations and the 
wisdom of measuring the serum 
concentrations of these seven antipsy-
chotics metabolised by CYP3A4 when 
possible.
clozApIne cAn cAuse InflAmmAtIon
Clozapine can also cause inflamma-
tion, although the mechanisms are 
not completely understood. Most 
cases of clozapine- induced inflam-
mation occur during titration and 
the most typical manifestations are 
CRP elevations, fever and/or myocar-
ditis.15 Other rarer forms have been 
described and include serositis, 
pneumonitis/alveolitis, hepatitis, 
pancreatitis, nephritis, colitis and 
dermatological disorders.15
Australia appears to have almost 
10–100 times more clozapine- induced 
myocarditis than European countries. 
Drug agencies from various countries 
send their data to a WHO database 
called VigiBase.16 In July 2019, there 
were 3048 reports of myocarditis asso-
ciated with clozapine, which resulted 
in 6% lethality (170 fatal outcomes). 
Australia provided >1500 of those 
reports. Most individual countries 
from continental Europe provided 
<30 reports. In the view of Austra-
lian experts,17 a 3% incidence rate 
of clozapine- induced myocarditis in 
Australia is explained solely by their 
intensive cardiac monitoring during 
titration, which is not practiced in 
other countries. Psychiatrists in conti-
nental Europe, on the other hand, 
titrate their patients slowly and rarely 
diagnose clozapine- induced myocar-
ditis. In a real- world study with 3262 
clozapine patients from the Danish 
registry, Rohde et al18 found a 0.03% 
incidence of myocarditis within the 
first 2 months of treatment. Based 
on a 3% incidence of myocarditis 
according to Australian data and a 
6% death rate due to lack of cardiac 
monitoring, six deaths (3% multi-
plied by 6% is 0.18% and 0.18% of 
3262 is six deaths) were expected in 
that Danish study, but no myocarditis 
deaths were identified within the first 
2 months of clozapine treatment.18
To understand the paradox of 
clozapine myocarditis, one needs 
to remember that inflammation 
decreases clozapine metabolism and 
then realise that clozapine can also 
cause inflammation. The history of 
lamotrigine- induced Stevens- Johnson 
syndrome provides further under-
standing.19 Lamotrigine- induced 
Stevens- Johnson syndrome was associ-
ated with rapid dose escalation and/
or normal titration in patients taking 
an inhibitor, such as valproic acid. 
The first sign that the titration is too 
fast for that patient is usually a skin 
rash. If the escalation continues, auto- 
antibodies develop, leading to full- 
blown Stevens- Johnson syndrome. 
Therefore, after the first approval, 
the pharmaceutical company had to 
reformulate the lamotrigine titration 
by halving the dose during co- pre-
scription of valproic acid. Similarly, 
we propose that, first, a clozapine 
titration that is too fast leads to CRP 
elevations and/or fever; second, 
cytokine release decreases clozapine 
metabolism and this causes a posi-
tive feedback mechanism; Third, if 
the clozapine titration continues, the 
inflammation evolves into myocar-
ditis, probably with the development 
of auto- antibodies.
This model was supported by five 
published cases of clozapine- induced 
myocarditis in New York.20 After their 
data was provided to the first author, 
four cases were found to have rapid 
titration and the other case could 
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not tolerate a low clozapine dose of 
25 mg/day, which is compatible with 
being a US clozapine PM. In two of 
the five patients clozapine levels 
were available and they were compat-
ible with a decrease in clozapine 
clearance.20
Following this model, clozapine- 
induced myocarditis can be 
prevented by using slow, personalised 
titration: (1) with further slowing for 
Asians treated by Western psychia-
trists, including Australians, who were 
trained to use Caucasian- level titra-
tion in all their patients; (2) consid-
ering reversible cases of clozapine 
PM status by stopping the co- prescrip-
tion of inhibitors, such as valproic 
acid and oral contraceptives, and 
requiring normal CRP before starting 
clozapine; and (3) considering 
extremely slow titration for cases of 
clozapine PMs in which the cause 
cannot be removed: extreme obesity 
or an absolutely needed co- pre-
scribed inhibitor. When clozapine 
dose escalation is associated with an 
abnormal CRP, cytokines are being 
released and the titration is too fast 
for that individual patient. Clozapine 
dose escalation needs to be held until 
CRP is normal.
To avoid the risk of myocarditis in 
Asians, we recommend starting with 
12.5 mg as the first dose, followed 
by targets of 50 mg/day on day 7, 
100 mg/day on day 14 and 150 mg/
day on day 21. Moreover, Asian 
companies producing clozapine 
should consider developing tables 
of 5 or 10 mg to facilitate slower 
titrations for Asian clozapine PMs.6 
In the absence of formulation with 
clozapine doses lower than 12.5 mg, 
for Asians with severe obesity or with 
co- prescription of a medication with 
potential to be a clinically- relevant 
inhibitor of clozapine metabolism 
(eg, valproic acid or an oral contra-
ceptive), we recommend starting with 
12.5 mg as the first dose, followed by 
targets of 25 mg/day on day 7, 50 mg/
day on day 14 and 75 mg/day on day 
21.
In summary, data from (1) the 
lamotrigine literature; (2) the clinical 
experience of the authors; (3) the 
review of TDM studies from the US, 
Europe and Asia; and (4) VigiBase 
has been used to reframe the myocar-
ditis debate. Myocarditis is extremely 
rare in non- Australian countries 
and can be avoided by slow, person-
alised titration. The high incidence 
of clozapine- induced myocarditis in 
Australia is probably explained by 
titration that may be fast for Cauca-
sians and is risky for Asian patients 
or for Caucasians taking an inhibitor, 
such as valproic acid.
clozApIne mAy be AssocIAted wIth 
IncreAsed rIsk of InfectIon
Clinicians all over the world know 
that on rare occasions clozapine can 
cause agranulocytosis since this infor-
mation is included in the clozapine 
package inserts and most drug agen-
cies require white cell counts to start 
clozapine. The mechanism is not well 
understood but it is believed that, in 
these patients, antibodies are devel-
oped against the neutrophils. The 
peak incidence occurs at 1 month of 
exposure and declines to negligible 
levels after 1 year of treatment.21 A 
recent meta- analysis provided a preva-
lence of agranulocytosis of 0.4% (95% 
CI: 0.3% to 0.6%); deaths caused 
by agranulocytosis were 0.05% (CI: 
0.03% to 0.09%).22 This widespread 
awareness by clinicians is reflected in 
the almost 35 000 reports of neutro-
penia in VigiBase with the number of 
fatal outcomes only in the 500s (2% 
relative lethality).16
More importantly, clinicians may 
not be aware that even in the absence 
of neutropenia, clozapine has been 
associated with a possible increased 
infection risk. Landry et al,23 based on 
case reports, proposed that clozapine 
may increase the risk of tuberculosis 
and, based on a chart review in a 
Canadian hospital, may be associ-
ated with increased use of antibiotics. 
Large studies in clozapine patients 
using the registries of Taiwan24 and 
Denmark25 verified an increased risk 
of tuberculosis with an adjusted risk 
ratio of 1.63 (95% CI: 1.10 to 2.40; 
p = 0.014)24 and increased antibiotic 
use with a relative risk of 1.43 (95% 
CI: 1.26 to 1.61, p<0.001).25 In a 
British case- control study, a higher 
proportion of the clozapine- treated 
group reported taking more than five 
courses of antibiotics in the preceding 
year, 5.3% (5/123) vs 1% (1/111) in 
controls taking other antipsychotics, 
and this was associated with an 
increased percentage of patients with 
low values for all immunoglobulins.26 
In an vitro study, clozapine increased 
the production of the interleukin-1 
receptor antagonist.27
Regarding possible increased infec-
tion risk in the absence of agranu-
locytosis, we only recommend that 
clinicians tell clozapine patients to 
avoid close contact with contagious 
people.
clozApIne mAy be more strongly 
AssocIAted wIth pneumonIA thAn 
wIth other InfectIons
The second section suggests that 
infection may be associated with 
clozapine intoxication and the fourth 
and prior section that clozapine 
may increase infection risk possibly 
by interfering with immunological 
defenses. As pneumonia is one of 
the most frequent infections, it is 
not surprising to find in the litera-
ture that pneumonia may be asso-
ciated with clozapine intoxication 
and that clozapine, by interfering 
with immunological mechanisms, 
may increase the risk of pneumonia. 
Moreover, attentive reading of the 
literature suggests that clozapine and 
pneumonia have strong bidirectional 
associations beyond what has been 
described in prior sections.
In 2005, after studying post- 
marketing surveillance data, the FDA 
proposed that, by interfering with 
swallowing, antipsychotics were asso-
ciated with increases in pneumonia 
in the elderly and this contributed 
to mortality in this population.27 
Although clozapine is rarely used in 
the elderly, its US package insert, as 
with other second- generation antipsy-
chotics, was modified to include this 
warning. Then Kuo et al,28 using the 
Taiwanese registry, demonstrated that 
clozapine may be the antipsychotic 
most closely associated with pneu-
monia. As a matter of fact, compared 
with other antipsychotics, clozapine 
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may be associated with a greater 
number of pneumonia cases and 
greater mortality.16 More importantly, 
clinicians need to be aware that pneu-
monia may be among the greatest 
causes of mortality in clozapine 
patients. VigiBase had >6000 reports 
of broadly- defined pneumonia in 
clozapine patients with >2000 lethal 
outcomes. To get an accurate perspec-
tive, clinicians need to be aware that 
the broad definitions of agranulocy-
tosis or myocarditis were associated 
with lethal outcomes in the 500s.16
Before describing which known 
mechanism can explain the strong 
association between clozapine and 
pneumonia, we have to acknowl-
edge that in countries other than 
China clozapine is mainly used for 
treatment- resistant schizophrenia. 
Thus, in countries other than China, 
the association between clozapine and 
pneumonia may be partly explained 
by the greater severity of illness in 
clozapine patients, who are frequently 
the most treatment- refractory 
patients with relatively high rates of 
smoking. Therefore, the contributing 
effects of the severity level of mental 
illness on pneumonia needs to be 
further explored by future studies 
in clozapine patients. On the other 
hand, clozapine has specific effects 
independent of the greater severity 
of illness in the clozapine patients, 
since using mirror- image design in 
the Danish registry,Rhode et al.29
Rhode et al29 found that clozapine 
gave the largest absolute increase in 
pneumonia risk although it did not 
reach significance, probably due to 
the relatively small sample size. In 
the year before clozapine, there were 
1.22% (23/1872) patients with pneu-
monia and in the first year 1.87% 
(35/1872). This is an increase of 
0.64% (12/1872) (p=0.10).
Clozapine, as with any other anti-
psychotic, can interfere with swal-
lowing, increasing the potential for 
aspiration.27 The potential for aspi-
ration and aspiration pneumonia 
during antipsychotic treatment may 
be further increased by sedation 
and hypersalivation.27 As clozapine 
is more prone to cause sedation 
and hypersalivation than other 
antipsychotics,27 it is not surprising 
that clozapine may be more strongly 
associated with aspiration pneu-
monia. Assuming that clozapine is 
associated with immunological abnor-
malities, this may also explain an 
increased risk for other types of pneu-
monia not associated with aspiration. 
Rarely, other severe clozapine ADRs, 
such as severe constipation compli-
cated with ileus, or myocarditis, can 
be complicated by pneumonia. Once 
pneumonia develops, clozapine 
co- prescription may be particularly 
lethal and worse than other antipsy-
chotics. Severe inflammation during 
pneumonia releases cytokines that 
inhibit CYP1A2 expression and/or 
activity and increase serum clozapine 
concentrations, further increasing 
the risk of concentration- related 
ADRs including hypersalivation, seda-
tion, aspiration or even arrhythmia, 
creating very dangerous positive 
feedback.16
Our three sets of recommenda-
tions for infections in clozapine 
patients apply to the most important 
infection, pneumonia. The general 
preventive measures related to infec-
tion apply, including patient/family 
education and use of the lowest 
possible dosage providing effica-
cious response. Specific preventive 
measures for aspiration pneumonia 
are close monitoring of sedation and 
hypersalivation. Clozapine adminis-
tration should be moved around to 
the most convenient times in order 
to increase adherence and decrease 
these ADRs; treat hypersalivation, 
preferably with local antimuscarinic 
treatments which may have less risk 
of increasing the risk of constipation 
than oral anticholinergic drugs, such 
as benztropine, or biperiden. Discon-
tinuation of other co- medications 
associated with sedation and/or pneu-
monia risk should be considered. As 
benzodiazepines are associated with 
sedation, swallowing disturbances 
and pneumonia, clinicians may need 
to consider decreasing or discontin-
uing them to decrease the aspiration 
pneumonia risk. Although there is no 
data, it may not be unreasonable to 
give pneumonia vaccines to clozapine 
patients to decrease risk of pneumonia 
not associated with aspiration, but 
it cannot be ruled out that vaccines 
may not be as effective in clozapine 
patients due to clozapine effects on 
immunological mechanisms.
Based on our experience with 
pneumonia,12–14 we recommend that 
clinicians measure trough serum 
clozapine concentrations to person-
alise dosing during pneumonia. 
As the clozapine levels may not be 
immediately available and due to 
high lethality, we are convinced that 
the clozapine dose should be cut in 
half in all patients with pneumonia. 
Regarding antibiotic treatment, those 
such as ciprofloxacin and norflox-
acin, which are strong CYP1A2 inhibi-
tors, should not be used.
After the pneumonia has resolved, 
we make the same recommendation 
as after infections: return to the prior 
dose after the CRP has normalised 
and consider the lowest clozapine 
dose possible with the fewest ADRs 
in order to avoid the recurrence of 
pneumonia in the future.
Clozapine appears to be associ-
ated with significantly fewer deaths 
in patients continuously treated with 
clozapine compared with other anti-
psychotics. In a meta- analysis of 24 
studies, long- term, crude mortality 
rate ratios were not significantly lower 
in patients ever treated with clozapine 
during follow- up, but significantly 
lower in patients continuously treated 
with clozapine compared with patients 
using other antipsychotics (mortality 
rate ratio=0.56, 95% CI: 0.36 to 0.85, p 
=0.007).30 By being alert to the multi-
faceted association of clozapine with 
inflammation, clinicians may further 
decrease the mortality in clozapine 
patients.
In summary, clinicians need to 
remember that: (1) systemic inflam-
mations can increase clozapine level; 
(2) clozapine, by itself, can cause 
inflammation, particularly during 
titration that is too rapid for that 
patient; (3) clozapine may increase 
the risk of infection; and (4) more 
specifically, clozapine may be particu-
larly strongly associated with the risk 
of pneumonia. Pneumonia appears 
to be associated with high mortality in 
clozapine patients around the world. 
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Clinicians who are alert to the risk of 
pneumonia in clozapine patients may 
significantly decrease mortality in 
clozapine patients.
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